Collectively, these findings define the CP niche as one of the primary sites for A2AR action, whereby A2AR antagonist confers protection against EAE pathology. Thus, pharmacological targeting of the CP A2AR represents a novel therapeutic strategy for MS treatment by controlling immune cell trafficking across the CP. This evidence concerns the gene CP and myeloid sarcoma.